Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Rose Sheet: FDA cosmetic & supplement regulation insight

Key benefits:

Ask-the-Analyst™
Expert Analysis
Hear from news makers

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

View all content

Scrip

Merck KGaA Down-Plays Further Deals After Consumer Health Sell-Off

By John Davis 20 Apr 2018

The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater flexibility in business development activities, but reducing net debt has first claim on the funds.

Topic Business strategies Company analysis

View article
Scrip

TVM Raises White Flag On Biovertis and Morphochem

By Mike Ward 20 Apr 2018

Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.

Topic Company analysis Business strategies

View article
Datamonitor Healthcare

Datamonitor Healthcare Podcast 04 April 2018

By Jack Allen 09 Apr 2018

Zach McLellan & Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including analysis on Allogene's announcement that they are in-licensing the TALEN technology from Pfizer to commericalise and develop allogeneic, potentially leading to a strong acceleration of CART therapies.

Topic Drug development landscape

Full podcast
Scrip

IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?

By Mandy Jackson 06 Apr 2018

Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.

Topic Company analysis

View article
Scrip

FDA Refuse-To-File Letter For Alkermes Depression Drug Suggests A Lengthy Commercial Delay

By Jessica Merrill 06 Apr 2018

CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.

Topic FDA Drug approval

View article
Datamonitor Healthcare, Biomedtracker

Pharma Intelligence Commercial Solution: Beat Your Competition

05 Apr 2018

To beat your competition, turn to the combined power of Biomedtracker and Datamonitor Healthcare for the most reliable and timely information in the industry.

Topic Drug review

Full video
Biomedtracker

Biomedtracker 2018 Early Outlook Report

05 Apr 2018

What’s on the horizon for pharma in 2018? Find out with Biomedtracker’s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

Topic Drug development landscape

Single report
Biomedtracker

Biomedtracker 2018 Early Outlook Infographic

05 Apr 2018

For a look at the outcome of two catalysts featured in Biomedtracker’s Q4 2017 Outlook Report, download the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report.

Topic Drug development landscape

View infographic
Biomedtracker

2018 JP Morgan Healthcare Conference Review

05 Apr 2018

Don't miss out on this comprehensive review of all the presentations from the conference, complied by our analysts, with key points and expert insight, for you to download, for free. A full list of events and catalysts that were announced or updated during the conference is included in this report.

Topic Strategy

View white paper
Scrip

GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy

By Mandy Jackson 29 Mar 2018

GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.

Topic Business strategies

View article
Scrip

J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says

By Brenda Sandburg 29 Mar 2018

Bernstein analyst looks into J&J's average net price decline in 2017 and notes average sales price hikes for growth products Darzalex and Imbruvica are offset by price cuts for drugs facing competition. All products had single digit increases, though.

Topic Biosimilars

View article
Datamonitor Healthcare

Datamonitor Healthcare Podcast 16 March 2018

By Jack Allen 20 Mar 2018

Zach McLellan, Jack Allen, and guest analysts Louisa Joseph and Michael Haydock discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including results for Gilead's new HIV flagship product; Biktarvy, and the US approval of the HIV drug Trogarzo, the first for salvage patients.

Topic Clinical trials Infectious diseases

Full podcast
Scrip

Getting Women On Boards: LifeSci Advisors' After-Party Mission Is Valued But Achieving Results Is Hard

By Eleanor Malone 20 Mar 2018

LifeSci Advisors has thrown its back into getting more women on boards, and its efforts have been praised. However, with just 13 women placed in a year and a half, the task is not an easy one.

View article
Scrip

From Pharma Insider To Payer: Witty To Lead United's Optum

By Jessica Merrill 20 Mar 2018

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

Topic Drug review

View article
Datamonitor Healthcare

Datamonitor Healthcare Podcast 02 March 2018

By Jack Allen 09 Mar 2018

Zach McLellan, Jack Allen, and guest analyst Dan Chancellor discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast. Featuring analysis of the Sangamo Therapeutics and Gilead/Kite partnership for allogeneic oncology products & update on Restasis patent disputes.

Topic Company analysis

Full podcast

Latest headlines

Scrip

20 Apr 2018

Pipeline Watch: Phase III Updates For Eravacycline, Opdivo And Keytruda

Link
Scrip

19 Apr 2018

Publisher's Spotlight: The 2018 Scrip Awards Is Now Open For Entries

Link
Scrip

19 Apr 2018

Merck KGaA Down-Plays Further Deals After Consumer Health Sell-Off

Link
Scrip

19 Apr 2018

Shire Rejects Multiple Equity-Loaded Takeda Offers, Allergan Declines To Bid

Link
Scrip

19 Apr 2018

US Generic Drug Spending Declines In A New Development – IQVIA Report

Link
Scrip

19 Apr 2018

Experts Challenge GSK Triple Inhaled COPD Therapy Claims

Link
Scrip

19 Apr 2018

TVM Raises White Flag On Biovertis & Morphochem

Link
Scrip

19 Apr 2018

BenevolentAI Scoops $115M For AI Drug Development

Link
Scrip

19 Apr 2018

Novartis Allays Concerns Over Cosentyx Sales Miss

Link
Scrip

19 Apr 2018

INFOGRAPHIC: China Vs Cancer: An Infographic Snapshot

Link
Scrip

18 Apr 2018

With Back-To-Back FDA Holds, Solid Hopes To Regain Footing For Duchenne Candidate

Link
Scrip

18 Apr 2018

Struggling Fibrocell To Consider All Strategic Directions Going Forward

Link
Scrip

18 Apr 2018

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Link
Scrip

18 Apr 2018

Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

Link
Scrip

18 Apr 2018

AstraZeneca Bolstering India Play With $90m Investment Plan

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Get ahead with in-depth pharmaceutical competitive intelligence

​Master the marketplace

Relevant products

Below are the Product List

Rose Sheet: FDA cosmetic & supplement regulation insight

Datamonitor Healthcare: data analysis and insight

Scrip: industry news and insights

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Report store

Master the marketplace